ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 164 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2016. The put-call ratio across all filers is 1.24 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $219,671 | +0.7% | 4,762 | -12.4% | 0.00% | 0.0% |
| Q1 2023 | $218,104 | -31.4% | 5,439 | -20.7% | 0.00% | 0.0% |
| Q4 2022 | $317,916 | +9.6% | 6,862 | -2.1% | 0.00% | 0.0% |
| Q3 2022 | $290,000 | -26.2% | 7,007 | +6.3% | 0.00% | 0.0% |
| Q2 2022 | $393,000 | -38.0% | 6,593 | -24.6% | 0.00% | 0.0% |
| Q1 2022 | $634,000 | -33.3% | 8,739 | -22.7% | 0.00% | -50.0% |
| Q4 2021 | $951,000 | -34.5% | 11,311 | -29.7% | 0.00% | -50.0% |
| Q3 2021 | $1,452,000 | +5.6% | 16,098 | +11.7% | 0.00% | 0.0% |
| Q2 2021 | $1,375,000 | -56.0% | 14,418 | -47.4% | 0.00% | -60.0% |
| Q1 2021 | $3,123,000 | -10.3% | 27,428 | +9.0% | 0.01% | -23.1% |
| Q4 2020 | $3,482,000 | +138.0% | 25,153 | +41.3% | 0.01% | +85.7% |
| Q3 2020 | $1,463,000 | +3.0% | 17,800 | -2.0% | 0.01% | -12.5% |
| Q2 2020 | $1,421,000 | +163.6% | 18,164 | +49.7% | 0.01% | +100.0% |
| Q1 2020 | $539,000 | -40.4% | 12,136 | -42.8% | 0.00% | 0.0% |
| Q4 2019 | $905,000 | -8.5% | 21,199 | -8.3% | 0.00% | -33.3% |
| Q3 2019 | $989,000 | -34.2% | 23,117 | -2.3% | 0.01% | -33.3% |
| Q2 2019 | $1,503,000 | -19.7% | 23,665 | -12.3% | 0.01% | -18.2% |
| Q1 2019 | $1,872,000 | +82.6% | 26,991 | +14.5% | 0.01% | +57.1% |
| Q4 2018 | $1,025,000 | -51.9% | 23,564 | -15.5% | 0.01% | -50.0% |
| Q3 2018 | $2,129,000 | -1.8% | 27,882 | -1.2% | 0.01% | -6.7% |
| Q2 2018 | $2,168,000 | +42.6% | 28,209 | -5.4% | 0.02% | +50.0% |
| Q1 2018 | $1,520,000 | +9.7% | 29,813 | -0.2% | 0.01% | 0.0% |
| Q4 2017 | $1,386,000 | -5.7% | 29,887 | +8.4% | 0.01% | -28.6% |
| Q3 2017 | $1,469,000 | -9.2% | 27,575 | +5.9% | 0.01% | -12.5% |
| Q2 2017 | $1,617,000 | -13.3% | 26,035 | -5.4% | 0.02% | -20.0% |
| Q1 2017 | $1,865,000 | -20.4% | 27,522 | -17.4% | 0.02% | -23.1% |
| Q4 2016 | $2,343,000 | +12.1% | 33,319 | +13.0% | 0.03% | -10.3% |
| Q3 2016 | $2,091,000 | +23.4% | 29,480 | -14.9% | 0.03% | +31.8% |
| Q2 2016 | $1,694,000 | -22.0% | 34,631 | +0.9% | 0.02% | -26.7% |
| Q1 2016 | $2,173,000 | -49.2% | 34,326 | -10.0% | 0.03% | -42.3% |
| Q4 2015 | $4,280,000 | +29.1% | 38,151 | +10.8% | 0.05% | +10.6% |
| Q3 2015 | $3,316,000 | -2.5% | 34,432 | +3.7% | 0.05% | 0.0% |
| Q2 2015 | $3,401,000 | +84.8% | 33,217 | +12.1% | 0.05% | +113.6% |
| Q1 2015 | $1,840,000 | +85.3% | 29,637 | +30.9% | 0.02% | +83.3% |
| Q4 2014 | $993,000 | – | 22,633 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EcoR1 Capital, LLC | 519,119 | $40,605,000 | 3.00% |
| First Light Asset Management, LLC | 236,958 | $18,535,000 | 2.16% |
| SECTOR GAMMA AS | 108,734 | $8,505,000 | 1.76% |
| Rock Springs Capital Management LP | 646,841 | $50,596,000 | 1.39% |
| Atika Capital Management LLC | 79,000 | $6,180,000 | 0.80% |
| Capital Impact Advisors, LLC | 30,582 | $2,392,000 | 0.80% |
| FEDERATED HERMES, INC. | 4,080,359 | $319,166,000 | 0.79% |
| Rhenman & Partners Asset Management AB | 61,500 | $4,811,000 | 0.52% |
| Ikarian Capital, LLC | 73,500 | $5,749,000 | 0.46% |
| Capital International, Inc./CA/ | 477,858 | $37,378,000 | 0.46% |